EUROGIN 2018 – International Multidisciplinary HPV Congress
TBD LisbonLisbon, PORTUGAL Visit the Venue to read more
Dear friends and colleagues,
On behalf of the EUROGIN Organizing Committee, I am pleased to welcome you to EUROGIN 2018.
Lisbon continues to be an interesting destination for the EUROGIN congress, which takes place here for the second time, following the positive experience in 2011. Indeed, in the area of HPV-related diseases, the medical and scientific environment in Portugal are very productive and conducive to progress and renewal, based on active and dynamic research; with the support of motivated local medical and professional organizations.
The city offers an infrastructure which corresponds to the logistical requirements of this type of international conference.
Over the last decades, the EUROGIN congress has gained a sound reputation as one of the leading international meetings on human papillomavirus infection and related cancers. The key purpose of the event remains unchanged: offering a high-level scientific forum to encourage multidisciplinary interactions to build a bridge between research and clinical action. The members of the scientific committee cover the whole spectrum of expertise in the field of HPV induced infections and associated diseases. Thanks to this top-ranking committee our program offers up-to-date scientific information all HPV-related diseases.
The main focus of the EUROGIN 2018 congress concerns the perspective of eliminating HPV induced diseases. Universal immunization of the entire population is a tremendeous opportunity to reduce the burden of cervical ,ano-genital and oral cancer worldwide. Elimination of HPV related cancer is not an unrealistic perspective.
The program includes the presentation of preliminary results which underline the long-term protection of the HPV vaccine against invasive cervical cancer. These findings open also the perspective of efficient protection against other HPV-associated cancers.
Over four days the EUROGIN congress will offer a variety of learning opportunities from which attendees can choose: training courses, workshops, scientific sessions, clinical sessions, free communications and poster presentations.
In addition to the international program, the “Workshop Lusófono” in Portuguese language, with its program designed in collaboration with the major scientific societies, will offer a comprehensive overview of the latest findings in HPV-related diseases for delegates from Portuguese speaking countries. Precision-based cancer screening and prevention is now possible. New technology and risk algorithms allow us to increase the precision of screening and the sensitiviy of existing tools for early detection and immunization.
Applying recent advances in genomics, proteomics and immunogenetics enhances our understanding of the biology of premalignancy and allows to identify new targets for interception. It is time to benefit from the scientific revolution in our field and to implement the new technologies in the real world of screening, early detection and immunization.
These are some of the goals of the EUROGIN 2018 congress. Time for action is now. We look forward to welcoming you at an exciting congress in the beautiful city of Lisbon.
Joseph MonsonegoJoseph Monsonego
Chairman of the Scientific Committee
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Submission of an abstract implies the commitment that the presenting author registers for the EUROGIN 2018 Congress and that financial resources to attend are available;
1 • Authors are requested to register within 10 days after having received their provisional notification of acceptance.
Abstracts of authors not registered by September 15, 2018 will not be taken into consideration for the final program.
Abstract presenters who would like to benefit from the early bird registration rate (deadline is June 30) are advised to submit their abstract before June 20, 2018 and send a short notice to email@example.com
They will then receive notification of acceptance/refusal which will allow them to register at the early bird rate.
If the abstract presenter is registered with a group, please inform the Congress Secretariat at: firstname.lastname@example.org and indicate the person who booked the group registration.
2 • Abstracts must be submitted and presented in ENGLISH
3 • Abstracts should be prepared in accordance to the instructions below and submitted through the online system. Abstracts should comply with the editing instructions;
4 • For proffered papers (for Oral Communications sessions or Poster presentation), only ONE abstract is allowed per person duly registered for the congress;
5 • Original scientific material is welcome and preference is given to recent findings not yet published at the date of the Congress;
6 • Abstracts will be peer reviewed and evaluated by experts in one of the categories (topics) listed; they will be allocated for oral or poster presentation. Authors who do not wish to be considered for oral presentation are requested to indicate this when submitting. However, please note, that the Scientific Committee will make the final decision for the mode of presentation;
7 • The final decision of the Scientific Committee will be announced early September 2018.
8 • Authors agree that their abstract will be published in the congress abstract book (pdf document, no printed document will be issued)
9 • All accepted abstract submitters will receive confirmation by email. Please do not forget to indicate your correct email address and telephone number when submitting your abstract, as well as the email addresses of the main author and the presenter (the author who will present the paper at the conference).
The main author and the presenter can be the same person. They may also be identical to or different from the submitter);
10 • The main author and the presenter must be identified (by ticking the corresponding boxes)
11 • For further information and assistance please contact the scientific secretariat at email@example.com
Abstract submission deadline 2018-08-15
Contact No.: +33 1 44 40 01 20